デフォルト表紙
市場調査レポート
商品コード
1482443

感染症体外診断市場:地域別(北米、欧州、アジア太平洋、ラテンアメリカ、中東アフリカ):世界の産業分析、規模、シェア、成長、動向、予測、2024-2031年

Infectious Disease In-vitro Diagnostics Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

出版日: | 発行: Persistence Market Research | ページ情報: 英文 250 Pages | 納期: 2~5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
感染症体外診断市場:地域別(北米、欧州、アジア太平洋、ラテンアメリカ、中東アフリカ):世界の産業分析、規模、シェア、成長、動向、予測、2024-2031年
出版日: 2024年05月16日
発行: Persistence Market Research
ページ情報: 英文 250 Pages
納期: 2~5営業日
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社は、世界の感染症体外診断(IVD)市場を幅広く分析し、市場動向、成長促進要因、課題、新興動向に関する考察を提供しています。当レポートは、市場情勢をナビゲートするための詳細なデータや統計を提供し、利害関係者の包括的なガイドとして役立ちます。

世界の感染症体外診断市場は、世界の感染症流行の増加を背景に、2024年から2031年にかけて大きく成長する見通しです。この期間のCAGRは4.4%と予測され、市場は2024年の668億米ドルから2031年には902億米ドルに拡大すると予測されます。

主な洞察

  • 推定市場価値(2024年):668億米ドル
  • 予測市場価格(2031年)902億米ドル
  • 世界市場成長率(CAGR 2024年~2031年):4.4%

感染症体外診断市場- レポート範囲

体外診断薬は、感染症の検出と管理において重要な役割を果たし、効果的な患者ケアのために迅速かつ正確な結果を提供します。この市場には、細菌、ウイルス、寄生虫などの様々な感染因子を検出するために設計された、分子アッセイ、免疫アッセイ、ポイントオブケア検査などの幅広い診断検査が含まれます。

世界化、都市化、抗菌剤耐性などの要因に後押しされた感染症の発生率の増加が、診断検査の需要を牽引しています。さらに、現在進行中のCOVID-19パンデミックは、疾病の蔓延を抑制し公衆衛生の危機を管理するための強固な診断インフラと検査能力の重要性を浮き彫りにしています。

市場成長の促進要因:

感染症体外診断市場の成長には、HIV/AIDS、結核、マラリア、肝炎などの感染症罹患率の上昇など、いくつかの要因が寄与しています。さらに、新たな感染因子の出現や既存の病原体の再出現は、公衆衛生上の重大な課題となっており、診断能力の強化が必要とされています。

分子診断、次世代シーケンシング、迅速ポイントオブケア検査などの診断技術の進歩により、感染性病原体をより迅速かつ正確に検出することが可能になった。さらに、ヘルスケア支出の増加、感染症対策に対する政府の取り組み、早期診断の重要性に対する意識の高まりが、市場の成長をさらに後押ししています。

市場抑制要因:

前向きな成長見通しにもかかわらず、感染症体外診断市場は規制上のハードル、償還の問題、サプライチェーンの混乱など、一定の課題に直面しています。診断検査の承認に関する厳しい規制要件や償還の制限は、メーカー、特に中小企業の市場参入を阻害する可能性があります。

さらに、特に資源が限られた環境では、診断検査インフラの導入の複雑さとコストが市場拡大の課題となっています。さらに、検査性能のばらつきや偽陽性・偽陰性の可能性は、診断精度や患者の転帰に影響を及ぼす可能性があり、ヘルスケアプロバイダーや患者の懸念につながっています。

市場機会:

感染症体外診断市場は、特に新規診断技術や検査プラットフォームの開発において、技術革新と拡大の機会を数多く提供しています。核酸増幅検査やマルチプレックスアッセイを含む分子診断の進歩は、感染症検出の感度、特異性、所要時間の改善をもたらします。

さらに、診断プラットフォームに人工知能や機械学習アルゴリズムを統合することで、データ解析と解釈が強化され、より正確で実用的な診断洞察が得られます。さらに、ポイントオブケア検査や分散型診断ソリューションの採用が進むことで、特に医療が行き届いていない遠隔地でのタイムリーな診断と治療が可能になります。

本レポートで扱う主な質問

  • 2024年から2031年までの感染症体外診断市場の期待値CAGRは?
  • 感染症体外診断市場の成長を促進する主な要因は何か?
  • 感染症体外診断市場で最大の市場シェアを占める地域は?
  • 感染症体外診断の世界市場における主要プレイヤーは?
  • 感染症体外診断市場の成長を維持するために、主要企業はどのような戦略を採用しているか?

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限

第3章 市場背景

  • 市場力学
  • シナリオ予測
  • 機会マップ分析
  • 製品ライフサイクル分析
  • 投資実現可能性マトリックス
  • PESTLEとポーター分析
  • 規制状況
  • 地域親市場見通し

第4章 世界の感染症体外診断市場分析

  • 過去の市場規模(金額)分析、2019-2023年
  • 現在および将来の市場規模(金額)予測、2024~2031年

第5章 製品タイプ別:世界の感染症体外診断市場分析

  • イントロダクション/主な調査結果
  • 過去の市場規模(金額)分析、2019-2023年
  • 現在および将来の市場規模(金額)分析・予測、2024-2031年
    • 機器
    • 試薬
    • サービス
  • 前年比成長動向分析、2019~2023年
  • 絶対的収益の機会分析、2024-2031年

第6章 技術別:世界の感染症体外診断市場分析

  • イントロダクション/主な調査結果
  • 過去の市場規模(金額)分析、2019-2023年
  • 現在および将来の市場規模(金額)分析・予測、2024-2031年
    • 免疫測定
    • 分子診断
    • 微生物学
    • その他のテクノロジー
  • 前年比成長動向分析、2019~2023年
  • 絶対的収益の機会分析、2024-2031年

第7章 用途別:世界の感染症体外診断市場分析

  • イントロダクション/主な調査結果
  • 過去の市場規模(金額)分析、2019-2023年
  • 現在および将来の市場規模(金額)分析・予測、2024-2031年
    • MRSA
    • 連鎖球菌
    • クロストリジウム・ディフィシル
    • 呼吸器ウイルス
    • 結核と薬剤耐性結核
    • 淋病
    • HPV
    • HIV
    • C型肝炎
    • B型肝炎
    • COVID-19
    • その他のアプリケーション
  • 前年比成長動向分析、2019~2023年
  • 絶対的収益の機会分析、2024-2031年

第8章 最終用途別:世界の感染症体外診断市場分析

  • イントロダクション/主な調査結果
  • 過去の市場規模(金額)分析、2019-2023年
  • 現在および将来の市場規模(金額)分析・予測、2024-2031年
    • 注意する点
    • 中央研究所
    • その他の用途
  • 前年比成長動向分析、2019~2023年
  • 絶対的収益の機会分析、2024-2031年

第9章 地域別:世界の感染症体外診断市場分析

  • イントロダクション
  • 過去の市場規模(金額)分析、2019-2023年
  • 現在の市場規模(金額)分析・予測、2024-2031年
    • 北米
    • ラテンアメリカ
    • 欧州
    • アジア太平洋地域
    • 中東およびアフリカ
  • 地域別市場魅力度分析

第10章 北米の感染症体外診断市場分析(国別)

第11章 ラテンアメリカの感染症体外診断市場分析(国別)

第12章 欧州の感染症体外診断市場分析(国別)

第13章 アジア太平洋感染症体外診断市場分析(国別)

第14章 中東およびアフリカの感染症体外診断市場分析(国別)

第15章 主要国の感染症体外診断市場分析

  • 米国
  • カナダ
  • ブラジル
  • メキシコ
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • ロシア
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル

第16章 市場構造分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 主要企業の市場シェア分析

第17章 競合分析

  • 競合の詳細
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Abbott
    • Quidel Corporation
    • OraSure Technologies, Inc
    • Hologic Inc.
    • Cepheid
    • Qiagen
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthcare GmbH
    • Bio-Rad Laboratories, Inc.

第18章 使用される前提条件と頭字語

第19章 調査手法

目次
Product Code: PMRREP33205

Persistence Market Research presents an extensive analysis of the global Infectious Disease In-vitro Diagnostics (IVD) Market, providing insights into market dynamics, growth drivers, challenges, and emerging trends. This report serves as a comprehensive guide for stakeholders, offering detailed data and statistics for navigating the market landscape.

The global infectious disease in-vitro diagnostics market is poised for significant growth between 2024 and 2031, driven by the increasing prevalence of infectious diseases worldwide. With a projected CAGR of 4.4% during this period, the market is estimated to expand from USD 66.8 billion in 2024 to USD 90.2 billion by 2031.

Key Insights:

  • Estimated Market Value (2024): USD 66.8 Billion
  • Projected Market Value (2031): USD 90.2 Billion
  • Global Market Growth Rate (CAGR 2024 to 2031): 4.4%

Infectious Disease In-vitro Diagnostics Market - Report Scope:

In-vitro diagnostics play a crucial role in the detection and management of infectious diseases, providing rapid and accurate results for effective patient care. The market encompasses a wide range of diagnostic tests, including molecular assays, immunoassays, and point-of-care tests, designed to detect various infectious agents such as bacteria, viruses, and parasites.

The increasing incidence of infectious diseases, fueled by factors such as globalization, urbanization, and antimicrobial resistance, drives the demand for diagnostic testing. Furthermore, the ongoing COVID-19 pandemic has underscored the importance of robust diagnostic infrastructure and testing capabilities to control disease spread and manage public health crises.

Market Growth Drivers:

Several factors contribute to the growth of the infectious disease IVD market, including the rising incidence of infectious diseases such as HIV/AIDS, tuberculosis, malaria, and hepatitis. Additionally, the emergence of new infectious agents and the re-emergence of existing pathogens pose significant public health challenges, necessitating enhanced diagnostic capabilities.

Advancements in diagnostic technologies, including molecular diagnostics, next-generation sequencing, and rapid point-of-care testing, enable faster and more accurate detection of infectious agents. Moreover, increased healthcare spending, government initiatives to combat infectious diseases, and growing awareness about the importance of early diagnosis further drive market growth.

Market Restraints:

Despite its positive growth outlook, the infectious disease IVD market faces certain challenges, including regulatory hurdles, reimbursement issues, and supply chain disruptions. Stringent regulatory requirements for diagnostic test approval and reimbursement limitations can hinder market access for manufacturers, particularly small and medium-sized enterprises.

Furthermore, the complexity and cost of implementing diagnostic testing infrastructure, especially in resource-limited settings, pose challenges to market expansion. Additionally, the variability in test performance and the potential for false-positive or false-negative results can impact diagnostic accuracy and patient outcomes, leading to concerns among healthcare providers and patients.

Market Opportunities:

The infectious disease IVD market presents numerous opportunities for innovation and expansion, particularly in the development of novel diagnostic technologies and test platforms. Advances in molecular diagnostics, including nucleic acid amplification tests and multiplex assays, offer improved sensitivity, specificity, and turnaround time for infectious disease detection.

Furthermore, the integration of artificial intelligence and machine learning algorithms into diagnostic platforms enhances data analysis and interpretation, leading to more accurate and actionable diagnostic insights. Moreover, the increasing adoption of point-of-care testing and decentralized diagnostic solutions enables timely diagnosis and treatment, particularly in underserved and remote areas.

Key Questions Addressed in the Report:

  • What is the Expected Value CAGR of the Infectious Disease IVD Market from 2024 to 2031?
  • What are the Key Factors Driving the Growth of the Infectious Disease IVD Market?
  • Which Region Holds the Largest Market Share in the Infectious Disease IVD Market?
  • Who are the Key Players in the Global Infectious Disease IVD Market?
  • What Strategies are Adopted by Leading Companies to Sustain Growth in the Infectious Disease IVD Market?

Competitive Landscape and Business Strategies:

Leading companies in the infectious disease IVD market include Roche Diagnostics, Abbott Laboratories, and bioMerieux SA. These companies focus on product innovation, research and development, and strategic partnerships to maintain their competitive edge.

Strategies such as expanding product portfolios, geographic expansion, and mergers and acquisitions are employed to enhance market presence and gain a competitive advantage. Furthermore, collaborations with healthcare organizations, government agencies, and research institutions facilitate the development and commercialization of novel diagnostic solutions.

Key Companies Profiled:

  • Roche Diagnostics
  • Abbott Laboratories
  • bioMerieux SA
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific, Inc.
  • Danaher Corporation
  • Hologic, Inc.
  • QIAGEN N.V.
  • Cepheid Inc.

Infectious Disease IVD Market Segmentation:

By Product Type:

  • Instruments
  • Reagents
  • Services

By Technology:

  • Immunoassay
  • Molecular Diagnostics
  • Microbiology
  • Other Technologies

By Application:

  • MRSA
  • Streptococcus
  • Clostridium Difficile
  • Respiratory Virus
  • TB and Drug-resistant TB
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Other Applications

By End-use:

  • Point of care
  • Central Laboratories
  • Other End-uses

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand-side Trends
  • 1.3. Supply-side Trends
  • 1.4. Technology Roadmap Analysis
  • 1.5. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations

3. Market Background

  • 3.1. Market Dynamics
    • 3.1.1. Drivers
    • 3.1.2. Restraints
    • 3.1.3. Opportunity
    • 3.1.4. Trends
  • 3.2. Scenario Forecast
    • 3.2.1. Demand in Optimistic Scenario
    • 3.2.2. Demand in Likely Scenario
    • 3.2.3. Demand in Conservative Scenario
  • 3.3. Opportunity Map Analysis
  • 3.4. Product Life Cycle Analysis
  • 3.5. Investment Feasibility Matrix
  • 3.6. PESTLE and Porter's Analysis
  • 3.7. Regulatory Landscape
    • 3.7.1. By Key Regions
    • 3.7.2. By Key Countries
  • 3.8. Regional Parent Market Outlook

4. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast, 2024-2031

  • 4.1. Historical Market Size Value (US$ Mn) Analysis, 2019-2023
  • 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2024-2031
    • 4.2.1. Y-o-Y Growth Trend Analysis
    • 4.2.2. Absolute $ Opportunity Analysis

5. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Product Type

  • 5.1. Introduction / Key Findings
  • 5.2. Historical Market Size Value (US$ Mn) Analysis By Product Type, 2019-2023
  • 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Product Type, 2024-2031
    • 5.3.1. Instruments
    • 5.3.2. Reagents
    • 5.3.3. Services
  • 5.4. Y-o-Y Growth Trend Analysis By Product Type, 2019-2023
  • 5.5. Absolute $ Opportunity Analysis By Product Type, 2024-2031

6. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Technology

  • 6.1. Introduction / Key Findings
  • 6.2. Historical Market Size Value (US$ Mn) Analysis By Technology, 2019-2023
  • 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Technology, 2024-2031
    • 6.3.1. Immunoassay
    • 6.3.2. Molecular Diagnostics
    • 6.3.3. Microbiology
    • 6.3.4. Other Technologies
  • 6.4. Y-o-Y Growth Trend Analysis By Technology, 2019-2023
  • 6.5. Absolute $ Opportunity Analysis By Technology, 2024-2031

7. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Application

  • 7.1. Introduction / Key Findings
  • 7.2. Historical Market Size Value (US$ Mn) Analysis By Application, 2019-2023
  • 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Application, 2024-2031
    • 7.3.1. MRSA
    • 7.3.2. Streptococcus
    • 7.3.3. Clostridium Difficile
    • 7.3.4. Respiratory Virus
    • 7.3.5. TB and Drug-resistant TB
    • 7.3.6. Gonorrhea
    • 7.3.7. HPV
    • 7.3.8. HIV
    • 7.3.9. Hepatitis C
    • 7.3.10. Hepatitis B
    • 7.3.11. COVID-19
    • 7.3.12. Other Applications
  • 7.4. Y-o-Y Growth Trend Analysis By Application, 2019-2023
  • 7.5. Absolute $ Opportunity Analysis By Application, 2024-2031

8. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By End-use

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size Value (US$ Mn) Analysis By End-use, 2019-2023
  • 8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End-use, 2024-2031
    • 8.3.1. Point of care
    • 8.3.2. Central Laboratories
    • 8.3.3. Other End-uses
  • 8.4. Y-o-Y Growth Trend Analysis By End-use, 2019-2023
  • 8.5. Absolute $ Opportunity Analysis By End-use, 2024-2031

9. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Region

  • 9.1. Introduction
  • 9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2019-2023
  • 9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2024-2031
    • 9.3.1. North America
    • 9.3.2. Latin America
    • 9.3.3. Europe
    • 9.3.4. Asia Pacific
    • 9.3.5. Middle East and Africa
  • 9.4. Market Attractiveness Analysis By Region

10. North America Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 10.2.1. By Country
      • 10.2.1.1. U.S.
      • 10.2.1.2. Canada
    • 10.2.2. By Product Type
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End-use
  • 10.3. Market Attractiveness Analysis
    • 10.3.1. By Country
    • 10.3.2. By Product Type
    • 10.3.3. By Technology
    • 10.3.4. By Application
    • 10.3.5. By End-use
  • 10.4. Key Takeaways

11. Latin America Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 11.2.1. By Country
      • 11.2.1.1. Brazil
      • 11.2.1.2. Mexico
      • 11.2.1.3. Rest of Latin America
    • 11.2.2. By Product Type
    • 11.2.3. By Technology
    • 11.2.4. By Application
    • 11.2.5. By End-use
  • 11.3. Market Attractiveness Analysis
    • 11.3.1. By Country
    • 11.3.2. By Product Type
    • 11.3.3. By Technology
    • 11.3.4. By Application
    • 11.3.5. By End-use
  • 11.4. Key Takeaways

12. Europe Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 12.2.1. By Country
      • 12.2.1.1. Germany
      • 12.2.1.2. U.K.
      • 12.2.1.3. France
      • 12.2.1.4. Spain
      • 12.2.1.5. Italy
      • 12.2.1.6. Russia
      • 12.2.1.7. Rest of Europe
    • 12.2.2. By Product Type
    • 12.2.3. By Technology
    • 12.2.4. By Application
    • 12.2.5. By End-use
  • 12.3. Market Attractiveness Analysis
    • 12.3.1. By Country
    • 12.3.2. By Product Type
    • 12.3.3. By Technology
    • 12.3.4. By Application
    • 12.3.5. By End-use
  • 12.4. Key Takeaways

13. Asia Pacific Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 13.2.1. By Country
      • 13.2.1.1. China
      • 13.2.1.2. Japan
      • 13.2.1.3. India
      • 13.2.1.4. South Korea
      • 13.2.1.5. Australia
      • 13.2.1.6. Rest of APAC
    • 13.2.2. By Product Type
    • 13.2.3. By Technology
    • 13.2.4. By Application
    • 13.2.5. By End-use
  • 13.3. Market Attractiveness Analysis
    • 13.3.1. By Country
    • 13.3.2. By Product Type
    • 13.3.3. By Technology
    • 13.3.4. By Application
    • 13.3.5. By End-use
  • 13.4. Key Takeaways

14. Middle East and Africa Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 14.2.1. By Country
      • 14.2.1.1. South Africa
      • 14.2.1.2. Saudi Arabia
      • 14.2.1.3. UAE
      • 14.2.1.4. Israel
      • 14.2.1.5. Rest of MEA
    • 14.2.2. By Product Type
    • 14.2.3. By Technology
    • 14.2.4. By Application
    • 14.2.5. By End-use
  • 14.3. Market Attractiveness Analysis
    • 14.3.1. By Country
    • 14.3.2. By Product Type
    • 14.3.3. By Technology
    • 14.3.4. By Application
    • 14.3.5. By End-use
  • 14.4. Key Takeaways

15. Key Countries Infectious Disease In-vitro Diagnostics Market Analysis

  • 15.1. U.S.
    • 15.1.1. Pricing Analysis
    • 15.1.2. Market Share Analysis, 2024
      • 15.1.2.1. By Product Type
      • 15.1.2.2. By Technology
      • 15.1.2.3. By Application
      • 15.1.2.4. By End-use
  • 15.2. Canada
    • 15.2.1. Pricing Analysis
    • 15.2.2. Market Share Analysis, 2024
      • 15.2.2.1. By Product Type
      • 15.2.2.2. By Technology
      • 15.2.2.3. By Application
      • 15.2.2.4. By End-use
  • 15.3. Brazil
    • 15.3.1. Pricing Analysis
    • 15.3.2. Market Share Analysis, 2024
      • 15.3.2.1. By Product Type
      • 15.3.2.2. By Technology
      • 15.3.2.3. By Application
      • 15.3.2.4. By End-use
  • 15.4. Mexico
    • 15.4.1. Pricing Analysis
    • 15.4.2. Market Share Analysis, 2024
      • 15.4.2.1. By Product Type
      • 15.4.2.2. By Technology
      • 15.4.2.3. By Application
      • 15.4.2.4. By End-use
  • 15.5. Germany
    • 15.5.1. Pricing Analysis
    • 15.5.2. Market Share Analysis, 2024
      • 15.5.2.1. By Product Type
      • 15.5.2.2. By Technology
      • 15.5.2.3. By Application
      • 15.5.2.4. By End-use
  • 15.6. U.K.
    • 15.6.1. Pricing Analysis
    • 15.6.2. Market Share Analysis, 2024
      • 15.6.2.1. By Product Type
      • 15.6.2.2. By Technology
      • 15.6.2.3. By Application
      • 15.6.2.4. By End-use
  • 15.7. France
    • 15.7.1. Pricing Analysis
    • 15.7.2. Market Share Analysis, 2024
      • 15.7.2.1. By Product Type
      • 15.7.2.2. By Technology
      • 15.7.2.3. By Application
      • 15.7.2.4. By End-use
  • 15.8. Spain
    • 15.8.1. Pricing Analysis
    • 15.8.2. Market Share Analysis, 2024
      • 15.8.2.1. By Product Type
      • 15.8.2.2. By Technology
      • 15.8.2.3. By Application
      • 15.8.2.4. By End-use
  • 15.9. Italy
    • 15.9.1. Pricing Analysis
    • 15.9.2. Market Share Analysis, 2024
      • 15.9.2.1. By Product Type
      • 15.9.2.2. By Technology
      • 15.9.2.3. By Application
      • 15.9.2.4. By End-use
  • 15.10. Russia
    • 15.10.1. Pricing Analysis
    • 15.10.2. Market Share Analysis, 2024
      • 15.10.2.1. By Product Type
      • 15.10.2.2. By Technology
      • 15.10.2.3. By Application
      • 15.10.2.4. By End-use
  • 15.11. China
    • 15.11.1. Pricing Analysis
    • 15.11.2. Market Share Analysis, 2024
      • 15.11.2.1. By Product Type
      • 15.11.2.2. By Technology
      • 15.11.2.3. By Application
      • 15.11.2.4. By End-use
  • 15.12. Japan
    • 15.12.1. Pricing Analysis
    • 15.12.2. Market Share Analysis, 2024
      • 15.12.2.1. By Product Type
      • 15.12.2.2. By Technology
      • 15.12.2.3. By Application
      • 15.12.2.4. By End-use
  • 15.13. India
    • 15.13.1. Pricing Analysis
    • 15.13.2. Market Share Analysis, 2024
      • 15.13.2.1. By Product Type
      • 15.13.2.2. By Technology
      • 15.13.2.3. By Application
      • 15.13.2.4. By End-use
  • 15.14. South Korea
    • 15.14.1. Pricing Analysis
    • 15.14.2. Market Share Analysis, 2024
      • 15.14.2.1. By Product Type
      • 15.14.2.2. By Technology
      • 15.14.2.3. By Application
      • 15.14.2.4. By End-use
  • 15.15. Australia
    • 15.15.1. Pricing Analysis
    • 15.15.2. Market Share Analysis, 2024
      • 15.15.2.1. By Product Type
      • 15.15.2.2. By Technology
      • 15.15.2.3. By Application
      • 15.15.2.4. By End-use
  • 15.16. South Africa
    • 15.16.1. Pricing Analysis
    • 15.16.2. Market Share Analysis, 2024
      • 15.16.2.1. By Product Type
      • 15.16.2.2. By Technology
      • 15.16.2.3. By Application
      • 15.16.2.4. By End-use
  • 15.17. Saudi Arabia
    • 15.17.1. Pricing Analysis
    • 15.17.2. Market Share Analysis, 2024
      • 15.17.2.1. By Product Type
      • 15.17.2.2. By Technology
      • 15.17.2.3. By Application
      • 15.17.2.4. By End-use
  • 15.18. UAE
    • 15.18.1. Pricing Analysis
    • 15.18.2. Market Share Analysis, 2024
      • 15.18.2.1. By Product Type
      • 15.18.2.2. By Technology
      • 15.18.2.3. By Application
      • 15.18.2.4. By End-use
  • 15.19. Israel
    • 15.19.1. Pricing Analysis
    • 15.19.2. Market Share Analysis, 2024
      • 15.19.2.1. By Product Type
      • 15.19.2.2. By Technology
      • 15.19.2.3. By Application
      • 15.19.2.4. By End-use

16. Market Structure Analysis

  • 16.1. Competition Dashboard
  • 16.2. Competition Benchmarking
  • 16.3. Market Share Analysis of Top Players
    • 16.3.1. By Regional
    • 16.3.2. By Product Type
    • 16.3.3. By Technology
    • 16.3.4. By Application
    • 16.3.5. By End-use

17. Competition Analysis

  • 17.1. Competition Deep Dive
    • 17.1.1. Becton, Dickinson and Company
      • 17.1.1.1. Overview
      • 17.1.1.2. Product Portfolio
      • 17.1.1.3. Profitability by Market Segments
      • 17.1.1.4. Sales Footprint
      • 17.1.1.5. Strategy Overview
        • 17.1.1.5.1. Marketing Strategy
    • 17.1.2. bioMerieux SA
      • 17.1.2.1. Overview
      • 17.1.2.2. Product Portfolio
      • 17.1.2.3. Profitability by Market Segments
      • 17.1.2.4. Sales Footprint
      • 17.1.2.5. Strategy Overview
        • 17.1.2.5.1. Marketing Strategy
    • 17.1.3. Abbott
      • 17.1.3.1. Overview
      • 17.1.3.2. Product Portfolio
      • 17.1.3.3. Profitability by Market Segments
      • 17.1.3.4. Sales Footprint
      • 17.1.3.5. Strategy Overview
        • 17.1.3.5.1. Marketing Strategy
    • 17.1.4. Quidel Corporation
      • 17.1.4.1. Overview
      • 17.1.4.2. Product Portfolio
      • 17.1.4.3. Profitability by Market Segments
      • 17.1.4.4. Sales Footprint
      • 17.1.4.5. Strategy Overview
        • 17.1.4.5.1. Marketing Strategy
    • 17.1.5. OraSure Technologies, Inc
      • 17.1.5.1. Overview
      • 17.1.5.2. Product Portfolio
      • 17.1.5.3. Profitability by Market Segments
      • 17.1.5.4. Sales Footprint
      • 17.1.5.5. Strategy Overview
        • 17.1.5.5.1. Marketing Strategy
    • 17.1.6. Hologic Inc.
      • 17.1.6.1. Overview
      • 17.1.6.2. Product Portfolio
      • 17.1.6.3. Profitability by Market Segments
      • 17.1.6.4. Sales Footprint
      • 17.1.6.5. Strategy Overview
        • 17.1.6.5.1. Marketing Strategy
    • 17.1.7. Cepheid
      • 17.1.7.1. Overview
      • 17.1.7.2. Product Portfolio
      • 17.1.7.3. Profitability by Market Segments
      • 17.1.7.4. Sales Footprint
      • 17.1.7.5. Strategy Overview
        • 17.1.7.5.1. Marketing Strategy
    • 17.1.8. Qiagen
      • 17.1.8.1. Overview
      • 17.1.8.2. Product Portfolio
      • 17.1.8.3. Profitability by Market Segments
      • 17.1.8.4. Sales Footprint
      • 17.1.8.5. Strategy Overview
        • 17.1.8.5.1. Marketing Strategy
    • 17.1.9. F. Hoffmann-La Roche Ltd.
      • 17.1.9.1. Overview
      • 17.1.9.2. Product Portfolio
      • 17.1.9.3. Profitability by Market Segments
      • 17.1.9.4. Sales Footprint
      • 17.1.9.5. Strategy Overview
        • 17.1.9.5.1. Marketing Strategy
    • 17.1.10. Siemens Healthcare GmbH
      • 17.1.10.1. Overview
      • 17.1.10.2. Product Portfolio
      • 17.1.10.3. Profitability by Market Segments
      • 17.1.10.4. Sales Footprint
      • 17.1.10.5. Strategy Overview
        • 17.1.10.5.1. Marketing Strategy
    • 17.1.11. Bio-Rad Laboratories, Inc.
      • 17.1.11.1. Overview
      • 17.1.11.2. Product Portfolio
      • 17.1.11.3. Profitability by Market Segments
      • 17.1.11.4. Sales Footprint
      • 17.1.11.5. Strategy Overview
        • 17.1.11.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology